OvaScience Inc. (OVAS) Receives Consensus Rating of “Hold” from Analysts
Shares of OvaScience Inc. (NASDAQ:OVAS) have been assigned a consensus rating of “Hold” from the eight research firms that are currently covering the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.17.
Several research analysts have recently weighed in on the company. JPMorgan Chase & Co. lowered their target price on OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Friday, August 5th. JMP Securities reiterated a “neutral” rating on shares of OvaScience in a report on Wednesday, August 10th. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a report on Wednesday, August 10th. Finally, Credit Suisse Group AG reiterated a “sell” rating on shares of OvaScience in a report on Tuesday, July 12th.
Shares of OvaScience (NASDAQ:OVAS) traded up 0.15% during mid-day trading on Thursday, reaching $6.68. The company’s stock had a trading volume of 150,593 shares. The stock’s market cap is $237.55 million. The stock has a 50 day moving average of $7.03 and a 200-day moving average of $7.08. OvaScience has a one year low of $4.53 and a one year high of $15.39.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/ovascience-inc-ovas-receives-consensus-rating-of-hold-from-analysts.html
OvaScience (NASDAQ:OVAS) last issued its earnings results on Thursday, August 4th. The company reported ($0.62) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.21 million. OvaScience had a negative return on equity of 60.10% and a negative net margin of 13,906.35%. The business’s revenue for the quarter was up 530.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.64) EPS. On average, equities research analysts expect that OvaScience will post ($2.66) EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in shares of OvaScience by 26.3% in the second quarter. FMR LLC now owns 5,171,816 shares of the company’s stock worth $26,945,000 after buying an additional 1,076,787 shares during the last quarter. Janus Capital Management LLC raised its stake in shares of OvaScience by 12.2% in the second quarter. Janus Capital Management LLC now owns 3,860,236 shares of the company’s stock worth $20,111,000 after buying an additional 419,592 shares during the last quarter. Orbis Allan Gray Ltd purchased a new stake in shares of OvaScience during the first quarter worth about $19,839,000. BlackRock Fund Advisors raised its stake in shares of OvaScience by 29.9% in the second quarter. BlackRock Fund Advisors now owns 1,256,143 shares of the company’s stock worth $6,545,000 after buying an additional 288,953 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of OvaScience by 36.9% in the second quarter. Vanguard Group Inc. now owns 1,133,517 shares of the company’s stock worth $5,905,000 after buying an additional 305,783 shares during the last quarter. 80.70% of the stock is currently owned by institutional investors.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.